{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-007473","form_type":"8-K","ticker":"HRTX","cik":"0000818033","company_name":"HERON THERAPEUTICS, INC. /DE/","filed_at":"2023-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.169949+00:00","generated_at":"2026-06-18T05:07:38.976321+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CMS grants pass-through payment status for Heron's APONVIE effective April 1, 2023","bullets":["CMS approves three-year transitional pass-through status for APONVIE under C-code C9145 starting April 1, 2023.","APONVIE will be reimbursed separately outside surgical bundle at ASP+6% in HOPD and ASC settings.","APONVIE is the only PONV drug with Medicare reimbursement in both outpatient settings; launched March 6, 2023.","Over 70% of surgery opportunity is in outpatient settings; CEO says status facilitates patient access and billing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-007473","json":"https://secwatch.observer/filing/0000950170-23-007473.json","markdown":"https://secwatch.observer/filing/0000950170-23-007473.md","text":"https://secwatch.observer/filing/0000950170-23-007473.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818033/000095017023007473/0000950170-23-007473-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818033/000095017023007473/hrtx-20230313.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T05:07:38.976321+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}